


CuriRx, Inc Email Formats
Biotechnology Research • Woburn, Massachusetts, United States • 21-50 Employees
CuriRx, Inc Email Formats
CuriRx, Inc uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@curirx.com), used 64.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@curirx.com | 64.7% |
{first initial}{last name} | jdoe@curirx.com | 29.4% |
{last name} | doe@curirx.com | 5.9% |
Key Contact at CuriRx, Inc
Kaliappanadar Nellaiappan
Director Of Product Development
Company overview
| Headquarters | 205 Lowell Street, #1C, Wilmington, MA 01887, US |
| Phone number | +19786582962 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Stability Studies, Assay Development, IT, IM, Formulation Development, SC, Purification, Cell Line Development, Analytical Testing Services, Ocular, Dosage Form Development, Small Molecule, Product Release Testing, Upstream & Downstream, Biologics And Pharmaceuticals, Process Development And Technology Transfer, Large Molecule, All Modalities, Cmc Testing & Characterization, Drug Substance Testing, Liquid & Lyophilization Dosage Forms, Complex Injectable Formulations, Parenteral-Iv |
| Founded | 2012 |
| Employees | 21-50 |
| Socials |
About CuriRx, Inc
CuriRx, Inc is a certified minority woman owned company with 13,000 sqft, well equipped facility, established in 2012 and located in the Wilmington, MA. With combined experience of over 150 years, we offer high quality development services, in following areas • Analytical Development and testing services o Development, Qualification and Validation o Non-GMP and GMP testing and Stability studies o Product characterization o Particle Characterization • Drug Product Development services o Pre-Formulation and Formulation Development, Lyophilization Cycle Development o Parenteral (IM, IV, SC, IT), Ocular Nanotechnology We have successfully developed over 100 clinical formulations involving biological compounds. Our experience includes developing clinical formulations in both liquid and lyophilized dosage forms. The scientists at CuriRx have proven track record with successes in developing commercial products like Humira & Synagis (high con mAbs), Blincyto (Bispecific) and Gattex (Peptide) etc. • Bulk Drug Substance Development, CHOZN, CHOK1, HEK293, ExpiCHO, E,coli o Cell Line and Clone development o Transient transfection, creating stable pools. o Cell Culture 1Lbioreactors-50 Liter’s bioreactors & Purification o Process characterization We are actively hiring! For more details and to explore other open positions, please visit our career page on the website at https://curirx.com/careers/.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
CuriRx, Inc has 9 employees across 6 departments.
Departments
Number of employees
Funding Data
CuriRx, Inc has never raised funding before.
CuriRx, Inc Tech Stack
Discover the technologies and tools that power CuriRx, Inc's digital infrastructure, from frameworks to analytics platforms.
Security
Form builders
Form builders
JavaScript libraries
JavaScript libraries
UI frameworks
Page builders
JavaScript libraries
Documentation
Analytics
WordPress themes
Frequently asked questions
4.8
40,000 users



